OncoPharm

Foundations of OncoPharm: Hypercalcemia of Malignancy (in under 10 minutes)

Belzutifan, the 1st hypoxia-inducible factor (HIF) inhibitor is FDA-approved. Plus, expanded indication approvals for nivolumab, dostarlimab, lenvatinib/pembrolizumab, & Ivosidenib. Finally, my Top 5 Rolling Stones Songs (14:30).

Looking into the data behind the FDA & CDC's allowance for a booster mRNA vaccine for immunocompromised patients.

A recent patient experience serves as a reminder than TKIs, like cabozantinib, can produce many "minor" toxicities that can really add up and affect QOL.

Two recent publications to discuss: 1. The publication of a study discussed on our ASCO '21 Pod on acalabrutinib vs. ibrutinib and patient implications (https://ascopubs.org/doi/pdf/10.1200/JCO.21.01210) 2. A good illustration of the "crossing of the curves" and interpreting Kaplan-Meier curves using alloHSCT vs. 5-aza in MDS patients. https://ascopubs.org/doi/pdf/10.1200/JCO.20.02724

Two breast cancer updates (pembrolizumab in TNBC and adjuvant AI duration) and two cGVHD updates (belumosudil and ruxolitinib).

The almost-award winning* Landmarks in OncoPharm series returns to discuss the landmark Armstrong et al 2006 NEJM paper on using intraperitoneal chemotherapy in stage III ovarian cancer. Link: https://www.nejm.org/doi/full/10.1056/nejmoa052985 *not really

A case study in misbranding promotional materials and how to help FDA regulate them.

Discover the fascinating world of capecitabine, a prodrug of 5-FU, and learn about its unique activation in the body. Explore its historical development and the advantages it offers over traditional therapies. Delve into its uses across various cancers, highlighting important pharmacokinetics and the role of food intake in treatment. The discussion also uncovers potential toxicities and the increased risks for patients with DPD deficiency, alongside how dietary folate can influence treatment success.

A foundational topic in oncology - managing toxicities of tamoxifen and AI's in breast cancer patients. An excellent evidence-based review was recently published, and is worth our time on the Pod. Link: https://doi.org/10.1016/S1470-2045(20)30666-5